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Abstract
This editorial introduces a series of case studies that together highlight the use of health market interventions to
improve access to medicines in low-and-middle income countries (LMICs). It underscores the added value of using a
systems approach for a holistic understanding of how these interventions interact with the rest of the health system
and the intended and unintended consequences that result. It goes on to summarize key findings from each of the
studies and concludes with lessons for decision-makers on the design and implementation of market based
interventions in LMIC health systems
Editorial
Despite decades of implementation of national medicines
policies, medicines access, affordability, and use are still
problematic in many low and middle-income countries
(LMICs). Medicines account for a high proportion of out-
of-pocket (OOP) expenses in many LMICs and challenges
exist to ensure equitable access in the face of geographic,
economic and cultural barriers [2, 3]. Ineffective regulatory
systems, inadequate knowledge of disease and medicines
both on the part of providers (many of whom are
unlicensed) and patients, and wrong incentives are some
of the reasons for widespread inappropriate use of medi-
cines [6].
Markets have played an increasingly important role in
the health systems of LMICs over recent years, particularly
in drug development and in the delivery of related products
and services. A thorough understanding of health market
systems is needed to improve access to and use of medi-
cines [6]. New laws and regulations, training of providers,
and dissemination of information to relevant stakeholders
are some of the interventions that have been implemented.
These interventions have been effective in engaging with
health market actors, including pharmaceutical companies,
drug distributers, pharmacies, providers and consumers
and counteracting well known market failures [6]. Yet strat-
egies that depend on single interventions often fail. This is
because they do not adequately anticipate and account for
complex interactions among the range of stakeholders
mentioned above.
A systems approach to medicines is thus needed. A
systems approach examines medicines within the existent
complexity of a health system, and sheds light on how ‘in-
terventions in the pharmaceutical sector influence the rest
of the health system and vice versa’. It explicitly recognizes
that the development, production, procurement, distribu-
tion, prescription, dispensation and use of medicines de-
pend on the dynamic interaction of various health system
components [6]. It can provide new insights on why inter-
ventions succeed or fail, how they need to change over
time, and helps identify inputs, processes, outputs and out-
comes in need of impactful monitoring and evaluation.
Using a systems perspective can thus overcome limitations
of designing and evaluating narrowly-targeted interventions
and can provide vital information to design and implement
system-focused strategies [6].
Each of the three case studies that comprise this series
uses a systems approach to examine interventions that have
sought to improve access to medicines in LMICs through
the innovative use of health markets.
The first paper by Rutta et al. [4] reflects on the experi-
ence of Tanzania’s Accredited Drug Dispensing Outlet
(ADDO) program, a public-private partnership that seeks
to increase access to high-quality medicines at affordable
prices in areas lacking registered pharmacies through
engaging private retail drug shops. The authors examine
the program’s continued evolution in bringing together
training, business incentives, regulation, institution building
and information sharing. It also describes how the multi-
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pronged intervention strategy moved health system build-
ing blocks towards better access to medicines. The paper
identifies early and continuous engagement of stakeholders
at all levels as a key element of the program’s success.
Van Olmen et al. [5] examine how the innovative
MoPoTsyo peer educator program for diabetes patients
has enabled access to diabetes care in Cambodia, and
the stakeholder perceptions surrounding this approach.
They describe the evolution of the program from the self-
management of diabetes to a multi-component interven-
tion that simultaneously enabled access to affordable
medicines, provided services, and fostered integration of
peer educators with the country’s public health system.
The authors conclude that a combination of empowering
patients, strong organizational ability, engaging health sys-
tem actors at all levels, and simultaneous action on mul-
tiple barriers to care were central to achieving positive
program outcomes.
The final paper, by Ashigbie et al. [1], discusses the chal-
lenges posed by medicines reimbursement policies and
management implemented under Ghana’s National Health
Insurance Scheme (NHIS) and the consequences these
have on public and private providers and patients. Using
key informant interviews to understand accreditation,
drug reimbursement, medicines selection and purchasing
policies, and utilization, they found that while utilization
had increased under the NHIS, several factors under-
mined the NHIS’ effectiveness in improving affordable ac-
cess to needed medicines. These included delayed and low
reimbursement for medicines and inadequate regulatory
arrangements, which contributed to private providers
dropping out of the scheme.
There are several lessons that emerge from the case
studies. First, they highlight the importance of identify-
ing neglected stakeholders (e.g. drug shops in Tanzania,
peer educators in Cambodia) in addressing market fail-
ures in health markets. All three cases demonstrate the
need for early and continuous engagement of a wide range
of stakeholders. The Ghana study is an excellent example
of the consequences of program implementation that does
not adequately address key stakeholder concerns [6]. The
case studies also bring to the fore the importance of put-
ting in place dynamic, multi-component interventions. In-
terventions were dynamic because they evolved over time
in response to changed incentive structures, new technol-
ogy and new information; and they comprised multiple
components or addressed different elements of the health
system. Evaluations assessed potential unintended conse-
quences, which were successfully managed in Tanzania and
Cambodia, and are now of particular importance in Ghana
as the country continues to move forward on the path to
universal health coverage [2, 6]. Finally, the case studies
highlight the importance of strong institutional mecha-
nisms to underpin implementation of change, whether in
the form of training providers, creating effective regulatory
schemes, developing information systems, or strengthening
supply chains. Health system strengthening efforts towards
universal health coverage seek to reach all populations with
an expanding range of needed, high-quality services with-
out causing financial hardship. This also represents a major
opportunity to design and put in place reforms that are
built on the engagement of multiple stakeholders, sup-
ported by appropriate institutional arrangements, and in-
formed by evidence. Such evidence is generated through
monitoring intended and unintended consequences of
changes in health systems.
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